Filing Details
- Accession Number:
- 0001225208-19-003444
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-22 18:17:28
- Reporting Period:
- 2019-02-20
- Accepted Time:
- 2019-02-22 18:17:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 885725 | Boston Scientific Corp | BSX | Surgical & Medical Instruments & Apparatus (3841) | 042695240 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1529751 | A David Pierce | 300 Boston Scientific Way Marlborough MA 01752-1234 | Evp,Pres Medsurg | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-20 | 26,070 | $0.00 | 52,223 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2019-02-20 | 1,952 | $39.86 | 50,271 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-02-20 | 11,331 | $40.11 | 38,940 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Share Units | Acquisiton | 2019-02-20 | 16,318 | $0.00 | 16,318 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,318 | 2020-12-31 | 2020-12-31 | No | 4 | A | Direct |
Footnotes
- On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
- Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020.
Billionaire Hedge Funds
